Cellectar Biosciences, Inc. — Director's Dealing 2020

Jul 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cellectar Biosciences, Inc. (CLRB)
CIK: 0001279704
Period of Report: 2020-07-01

Reporting Person: Friend John E. II (VP, Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-01	Stock option (right to buy)	$1.34	A	100000	Acquired	2030-07-01	Common Stock (100000)	Direct

Footnotes

F1: The option shall vest in three equal installments beginning on the first anniversary of the date of grant.